Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity.

Nexøe-Larsen CC, Sørensen PH, Hausner H, Agersnap M, Baekdal M, Brønden A, Gustafsson LN, Sonne DP, Vedtofte L, Vilsbøll T, Knop FK

Diabetes, obesity & metabolism10 Jul 2018Cited by 42 (Europe PMC)

PMID29892986PMCIDPMC6220792DOI10.1111/dom.13420PepBankPUB-29892986

Read at source PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, liraglutide 3.0 mg did not change the 12-week maximum postprandial gallbladder ejection fraction versus placebo.
In plain wordsIn adults with overweight or obesity, liraglutide did not change how well the gallbladder emptied after a meal, compared with placebo.
Peptide
Liraglutide
Outcome
No significant change12-week maximum postprandial gallbladder ejection fraction (GBEFmax)
Study
n = 47
Comparator
Placebo
Analysis
Primary
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
0.6 mg increasing weekly in 0.6-mg steps to 3.0 mg · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Treatment difference
−3.7%
GBEFmax, 95% CI -13.1 to 5.7
Source sentences
Summary
Mean 12-week GBEF_max (treatment difference -3.7%, 95% confidence interval [CI] -13.1, 5.7) and area under the GBEF curve in the first 60 minutes (-390% × min, 95% CI -919, 140) did not differ for liraglutide 3.0 mg (n = 23) vs placebo (n = 24).
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomized 1:1 to once-daily subcutaneous liraglutide (n = 26) or placebo (n = 26), starting at 0.6 mg with 0.6-mg weekly increments to 3.0 mg, with nutritional and physical activity counselling.
Report a problemFND-2989298601
02HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, liraglutide 3.0 mg did not change the area under the gallbladder ejection fraction curve in the first 60 minutes versus placebo.
In plain wordsIn adults with overweight or obesity, liraglutide did not change early gallbladder emptying after a meal, compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeArea under the GBEF curve in the first 60 minutes
Study
n = 47
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
0.6 mg increasing weekly in 0.6-mg steps to 3.0 mg · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Treatment difference in AUC
−390 % × min
first 60 minutes, 95% CI -919 to 140
Source sentences
Summary
Mean 12-week GBEF_max (treatment difference -3.7%, 95% confidence interval [CI] -13.1, 5.7) and area under the GBEF curve in the first 60 minutes (-390% × min, 95% CI -919, 140) did not differ for liraglutide 3.0 mg (n = 23) vs placebo (n = 24).
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomized 1:1 to once-daily subcutaneous liraglutide (n = 26) or placebo (n = 26), starting at 0.6 mg with 0.6-mg weekly increments to 3.0 mg, with nutritional and physical activity counselling.
Report a problemFND-2989298602
03HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, the median time to maximum gallbladder ejection fraction was longer with liraglutide 3.0 mg than with placebo; no test result was given in the abstract.
In plain wordsIn adults with overweight or obesity, the gallbladder appeared to take longer to reach its peak emptying with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
IncreaseTime to GBEFmax
Study
n = 47
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
0.6 mg increasing weekly in 0.6-mg steps to 3.0 mg · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Median time to GBEFmax
151 minutes
liraglutide 3.0 mg
Median time to GBEFmax
77 minutes
placebo
Source sentences
Summary
The median (range) time to GBEF_max was 151 (11-240) minutes with liraglutide 3.0 mg and 77 (22-212) minutes with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Treatment with liraglutide did not affect the GBEF_max but appeared to prolong the time to GBEF_max .
Summary · context
Participants were randomized 1:1 to once-daily subcutaneous liraglutide (n = 26) or placebo (n = 26), starting at 0.6 mg with 0.6-mg weekly increments to 3.0 mg, with nutritional and physical activity counselling.
Report a problemFND-2989298603
04HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, the abstract states that findings after the first 0.6-mg liraglutide dose were similar to those at 12 weeks; it gives no separate numbers.
In plain wordsIn adults with overweight or obesity, results after a first small liraglutide dose were described as similar to the 12-week results.
Peptide
Liraglutide
Outcome
Direction not reportedGBEFmax after the first 0.6-mg dose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
0.6 mg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
Similar findings were noted after the first 0.6-mg liraglutide dose.
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomized 1:1 to once-daily subcutaneous liraglutide (n = 26) or placebo (n = 26), starting at 0.6 mg with 0.6-mg weekly increments to 3.0 mg, with nutritional and physical activity counselling.
Report a problemFND-2989298604
05HumanRandomized controlled trialSafety outcome
In adults with overweight or obesity in a 12-week trial of liraglutide versus placebo, gastrointestinal disorders were the most frequently reported adverse events; the abstract gives no split by arm.
In plain wordsIn a 12-week trial in adults with overweight or obesity, stomach and gut problems were the most commonly reported side effects.
Peptide
Liraglutide
Outcome
Direction not reportedGastrointestinal disorders
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.6 mg increasing weekly in 0.6-mg steps to 3.0 mg · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Gastrointestinal disorders, notably nausea and constipation, were the most frequently reported adverse events.
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomized 1:1 to once-daily subcutaneous liraglutide (n = 26) or placebo (n = 26), starting at 0.6 mg with 0.6-mg weekly increments to 3.0 mg, with nutritional and physical activity counselling.
Report a problemFND-2989298605
06HumanRandomized controlled trialSafety outcome
In adults with overweight or obesity in a 12-week trial of liraglutide versus placebo, nausea was among the most frequently reported adverse events; the abstract gives no split by arm.
In plain wordsIn a 12-week trial in adults with overweight or obesity, nausea was one of the most commonly reported side effects.
Peptide
Liraglutide
Outcome
Direction not reportedNausea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.6 mg increasing weekly in 0.6-mg steps to 3.0 mg · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Gastrointestinal disorders, notably nausea and constipation, were the most frequently reported adverse events.
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomized 1:1 to once-daily subcutaneous liraglutide (n = 26) or placebo (n = 26), starting at 0.6 mg with 0.6-mg weekly increments to 3.0 mg, with nutritional and physical activity counselling.
Report a problemFND-2989298606
07HumanRandomized controlled trialSafety outcome
In adults with overweight or obesity in a 12-week trial of liraglutide versus placebo, constipation was among the most frequently reported adverse events; the abstract gives no split by arm.
In plain wordsIn a 12-week trial in adults with overweight or obesity, constipation was one of the most commonly reported side effects.
Peptide
Liraglutide
Outcome
Direction not reportedConstipation
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.6 mg increasing weekly in 0.6-mg steps to 3.0 mg · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Gastrointestinal disorders, notably nausea and constipation, were the most frequently reported adverse events.
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomized 1:1 to once-daily subcutaneous liraglutide (n = 26) or placebo (n = 26), starting at 0.6 mg with 0.6-mg weekly increments to 3.0 mg, with nutritional and physical activity counselling.
Report a problemFND-2989298607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT02717858

A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.

Novo Nordisk A/Sn = 5216 Mar 2016 to 27 Feb 2017

Metabolism and Nutrition Disorder · Obesity

Trial page ClinicalTrials.govUpdated 28 Jun 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.